Brief: Kiromic Biopharma Pipeline To Prioritize A New Gamma Delta T-Cell Product Candidate
21/06/2022 15:01
June 21 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA PIPELINE TO PRIORITIZE A NEW GAMMA DELTA
T-CELL PRODUCT CANDIDATE
* KIROMIC BIOPHARMA- IND FOR NON-ENGINEERED DELTACEL/KB-GDT
TO BE
SUBMITTED IN SECOND HALF OF 2022, BEGINNING OF CLINICAL TRIAL
ACTIVATION EXPECTED BY YEAR-END
Source text for Eikon: ID:nBw9JSTpLa
Further company coverage: KRBP.O
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site